V
VTRS
VTRSUnverified17 segments tracked|5 years of data|Annual (10-K)
Total Revenue
$20.3B5.0%
FY2024
Operating Segments
17Active segments
Blended Margin
0.0%Operating margin
Highest Margin
0.0%Brands
Segment Shift
Brands has grown from 49.7% to 45.4% of total revenue since FY2020, with 0.0% operating margins. Meanwhile, Yupelri is the fastest growing at +8.0% YoY.
Segment Revenue Over Time
Revenue Mix
Segment Breakdown — FY2024
| Segment | Revenue | Op. Income | Margin | % of Total | YoY |
|---|---|---|---|---|---|
| Brands | $9.2B | $0 | 0.0% | 45.4% | -6.1% |
| Generics | $5.5B | $0 | 0.0% | 27.1% | -1.7% |
| Lipitor | $1.5B | $0 | 0.0% | 7.2% | -5.8% |
| Norvasc | $673M | $0 | 0.0% | 3.3% | -8.1% |
| Lyrica | $495M | $0 | 0.0% | 2.4% | -11.0% |
| Viagra | $396M | $0 | 0.0% | 2.0% | -7.7% |
| Epi Pen Auto Injectors | $392M | $0 | 0.0% | 1.9% | -11.4% |
| Creon | $328M | $0 | 0.0% | 1.6% | +7.6% |
| Celebrex | $286M | $0 | 0.0% | 1.4% | -13.6% |
| Effexor | $253M | $0 | 0.0% | 1.2% | -3.8% |
| Yupelri | $239M | $0 | 0.0% | 1.2% | +8.0% |
| Zoloft | $236M | $0 | 0.0% | 1.2% | +0.0% |
| Dymista | $188M | $0 | 0.0% | 0.9% | -6.0% |
| Influvac | $179M | $0 | 0.0% | 0.9% | -7.1% |
| Xalabrands | $166M | $0 | 0.0% | 0.8% | -13.9% |
| Amitiza | $149M | $0 | 0.0% | 0.7% | -5.0% |
| Xanax | $145M | $0 | 0.0% | 0.7% | -6.3% |
Want more? Unlock the full analysis.
Sign up free to access quarterly data, financial statements, trend analysis, geographic segments, Excel exports, and cross-company comparisons.
Get Started Free